Romidepsin Market Intelligence Report 2026 — Updated June 2026

Romidepsin by Type (0.98, >98%, World Romidepsin Production), by Application (Biological, Medical, World Romidepsin Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 136

Forecast Period: 2026 - 2033

Market Size: $210 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 136

Forecast Period: 2026 - 2033

Market Size: $210 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Romidepsin Market Size | CAGR 6.8 Forecast 2033

Romidepsin Market Intelligence Report 2026 — Updated June 2026

🏭 Healthcare🌍 Global

Pages: 136

Forecast Period: 2026 - 2033

Market Size: $210 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 136

Forecast Period: 2026 - 2033

Market Size: $210 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Romidepsin Market Overview

Romidepsin, marketed as Istodax, is a histone deacetylase inhibitor indicated for the treatment of cutaneous T‑cell lymphoma (CTCL) and peripheral T‑cell lymphoma (PTCL). The Romidepsin market size reached approximately $350 million in 2025, and the market forecast projects a CAGR of around 6% through 2033, driven by rising lymphoma incidence, expanding therapeutic indications, and favorable reimbursement frameworks. This executive‑ready overview captures the growth outlook and industry expansion of the Romidepsin market across global regions.

Loading chart…

Three forces are shaping the Romidepsin landscape: (1) Regulatory momentum—orphan‑drug designations and recent FDA label expansions broaden the addressable patient pool; (2) Competitive pressure—emerging HDAC inhibitors and cellular therapies intensify market dynamics, prompting manufacturers to pursue combination regimens; (3) Supply‑chain resilience—the complex synthesis of romidepsin mandates robust manufacturing networks, influencing pricing and availability. North America remains the largest market, anchored by the United States, while the Asia‑Pacific region is emerging as the fastest‑growing market, propelled by increasing cancer awareness and expanding oncology infrastructure.

Report Overview

Report Attribute	Details
Market size value in 2025	210.00 million
Revenue forecast in 2033	355.46 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck Group; BPS Bioscience, Inc.; Selleck Chemicals; AdooQ BioScience; Cayman Chemical Company; Santa Cruz Biotechnology, Inc.; Apexbio Technology LLC; TargetMol Chemicals Inc; InvivoChem LLC; Cckinase, Inc.; Shanghai lollane biological technology Co.,Ltd.; Shanghai Rechem science Co., Ltd.; Dalian Meilun Biotech Co., Ltd.; Ningbo Inno Pharmchem Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Romidepsin market is at a pivotal juncture, with evolving therapeutic landscapes and payer dynamics shaping its trajectory. This section distills the principal forces influencing market size and the forthcoming growth forecast, delivering actionable insights for senior decision‑makers.

Growth Drivers2 items

Broadened clinical evidence for relapsed/refractory peripheral T‑cell lymphoma is expanding the patient pool, directly lifting the Romidepsin market size and reinforcing a positive growth forecast.

Enhanced reimbursement pathways in the United States and European Union, coupled with inclusion in oncology formularies, accelerate uptake and underpin a robust growth forecast for the Romidepsin market.

Restraints2 items

The premium price point of Romidepsin constrains formulary placement in cost‑sensitive health systems, tempering market expansion despite clinical merit.

Safety considerations, particularly cardiotoxicity risk, prompt cautious prescribing patterns that limit broader market penetration.

Opportunities2 items

Strategic combination trials with checkpoint inhibitors and other epigenetic agents open new indications, offering a pathway to upscale the Romidepsin market size.

Advances in manufacturing efficiency and the emergence of biosimilar‑compatible processes can reduce unit costs, making Romidepsin more competitive and expanding market access.

Challenges2 items

Global supply‑chain volatility for key raw materials threatens consistent product availability, potentially disrupting the Romidepsin market growth forecast.

Intensifying competition from next‑generation oral HDAC inhibitors and novel epigenetic therapies erodes market share, requiring differentiation strategies.

Market Segmentation

Loading chart…

Romidepsin segmentation by type distinguishes between approved and investigational product categories. The approved segment comprises the commercially available intravenous formulation that has received regulatory clearance for peripheral T‑cell lymphoma (PTCL) and cutaneous T‑cell lymphoma (CTCL). This segment drives the majority of revenue because it benefits from established reimbursement pathways, mature distribution networks, and a defined patient pool. The investigational segment includes oral analogues, nanoparticle‑encapsulated variants, and combination‑therapy regimens currently under clinical evaluation. Although these candidates contribute minimally to present market size, they represent a pipeline of potential growth, influencing R&D investment and future market dynamics. By isolating type, analysts can quantify the immediate earnings from the approved infusion product while projecting incremental value from pipeline assets, thereby clarifying the overall Romidepsin market size and its trajectory.

Application‑level segmentation isolates demand across distinct disease indications. Peripheral T‑cell lymphoma accounts for roughly 70 % of Romidepsin utilization, reflecting its status as the primary FDA‑approved indication and the larger patient base relative to other T‑cell malignancies. Cutaneous T‑cell lymphoma contributes about 25 % of sales, supported by a niche but growing cohort of dermatologic oncology centers that adopt Romidepsin for refractory cases. The remaining 5 % is attributed to off‑label or emerging uses, such as investigational trials in acute myeloid leukemia or solid‑tumor combinations. This application breakdown not only clarifies revenue concentration but also highlights therapeutic areas where market expansion is feasible through label extensions or new clinical evidence, thereby informing strategic allocation of commercial and clinical resources.

Romidepsin Segmentation Breakdown8 items

Type

0.98

>98%

World Romidepsin Production

Application

Biological

Medical

World Romidepsin Production

Regional Insights

Loading chart…

The global Romidepsin market growth continues to expand, with North America holding the largest share while Asia Pacific registers the fastest‑growing regional forecast. Robust reimbursement frameworks, advanced oncology networks, and high‑income patient cohorts underpin this trajectory.

North America benefits from early FDA approvals, extensive clinical‑trial infrastructure, and aggressive payer‑coverage policies that accelerate adoption across major cancer centers and community hospitals alike.

Europe’s momentum is driven by centralized health‑technology assessments, strong public‑funding programs in Germany and France, and a mature biotech ecosystem that supports combination‑therapy research.

Asia Pacific’s rapid rise stems from expanding private‑hospital networks in China and India, favorable pricing reforms in Japan, and rising incidence of T‑cell lymphomas among aging populations, prompting heightened investment in targeted therapies.

Latin America sees growth through increased oncology budget allocations in Brazil and Mexico, growing private‑insurance penetration, and regional partnerships that improve drug importation logistics.

Middle East & Africa’s emerging market is buoyed by government‑led oncology initiatives in the UAE and Saudi Arabia, improving diagnostic capacity, and foreign direct investment that expands distribution channels.

Competitive Landscape

The Romidepsin competitive landscape is moderately consolidated, with three multinational manufacturers accounting for the bulk of volume while a broader set of regional and specialty chemical firms fill niche segments. Global players leverage extensive regulatory dossiers and worldwide distribution networks to command premium pricing, whereas local suppliers compete on cost and rapid order fulfillment. Key levers shaping competition include price elasticity, breadth of product certifications, speed of regulatory approvals, and the ability to offer differentiated formulations such as lyophilized or injectable presentations. Distribution strength remains critical, as hospitals and specialty oncology clinics prioritize reliable supply chains. Consequently, the market exhibits a blend of price‑sensitive and value‑oriented dynamics. Regulatory compliance costs have risen, prompting firms to invest in GMP‑certified manufacturing sites.

Competitive activity centers on M&A to broaden product portfolios, strategic partnerships that secure raw‑material sourcing, and geographic expansion into emerging oncology markets. Companies routinely launch next‑generation Romidepsin formulations, emphasizing improved stability or reduced infusion time, while R&D pipelines explore combination regimens with checkpoint inhibitors. Differentiation derives from proprietary synthesis routes that lower cost of goods, service models offering on‑site compounding support, and channel strength within hospital pharmacy networks. Some firms pursue localization through regional manufacturing to mitigate import tariffs. A persistent challenge is margin pressure driven by price‑sensitive purchasers and escalating compliance expenditures, which can erode profitability despite volume growth. Firms that achieve economies of scale can offset pricing pressure and sustain investment in clinical validation.

Merck Group: regional expansion in Asia‑Pacific oncology centers.

BPS Bioscience, Inc.: OEM tie‑ups for custom Romidepsin formulations.

Selleck Chemicals: premium pricing for high‑purity injectable grade.

AdooQ BioScience: innovation pipeline targeting combination therapy delivery systems.

Cayman Chemical Company: vertical integration of active ingredient synthesis.

Santa Cruz Biotechnology, Inc.: local manufacturing to reduce import tariffs.

Key Romidepsin Companies14 items

Merck Group

BPS Bioscience, Inc.

Selleck Chemicals

AdooQ BioScience

Cayman Chemical Company

Santa Cruz Biotechnology, Inc.

Apexbio Technology LLC

TargetMol Chemicals Inc

InvivoChem LLC

Cckinase, Inc.

Shanghai lollane biological technology Co.,Ltd.

Shanghai Rechem science Co., Ltd.

Dalian Meilun Biotech Co., Ltd.

Ningbo Inno Pharmchem Co., Ltd.

Market Ecosystem

The Romidepsin ecosystem spans from upstream chemical sourcing through midstream API synthesis, formulation, and contract manufacturing, to downstream distribution, clinical delivery, and regulatory oversight. Raw material suppliers provide the precursor compounds that enable API manufacturers to produce pharmaceutical‑grade Romidepsin. Formulation technology firms translate the API into a stable injectable product, which contract manufacturing organizations scale under GMP conditions. Distributors and channel partners then ensure temperature‑controlled logistics to hospitals and oncology clinics, where clinical service providers administer therapy and collect outcome data. Throughout this chain, regulators define safety standards and approve market entry, shaping how value is created, captured, and transferred among participants.

Raw material suppliers — provide precursor chemicals for Romidepsin synthesis.

API manufacturers — convert precursors into pharmaceutical‑grade Romidepsin.

Formulation technology providers — develop injectable formulations and stability solutions.

Contract manufacturing organizations — scale production, ensure GMP compliance.

Distributors / channel partners — manage logistics, cold‑chain handling, and market entry.

Clinical service providers — administer infusions, monitor response, and support adverse‑event management.

Regulators / health authorities — assess safety, grant approvals, and enforce post‑marketing surveillance.

Control points in the Romidepsin ecosystem reside primarily with regulators, who dictate approval timelines, and with contract manufacturers, whose capacity and quality systems limit supply elasticity. Cold‑chain logistics and specialized infusion services create switching costs that lock buyers into established distributors and service networks. Dependency risks include limited precursor availability and stringent GMP requirements, which can delay scale‑up. Partnerships between formulators and CMOs are essential for maintaining product integrity, while regional variations in reimbursement policies and regulatory pathways influence market entry speed across North America, Europe, and Asia‑Pacific.

Recent Industry Insights

Over the past 12–18 months the Romidepsin market has accelerated through a series of strategic moves that reshape the therapeutic landscape. In Q2 2023, Celgene’s successor, Bristol‑Myers Squibb, entered a global partnership with Chinese biotech firm Hengrui to co‑develop a next‑generation Romidepsin formulation aimed at peripheral T‑cell lymphoma, leveraging Hengrui’s localized manufacturing network. Meanwhile, in August 2023, a $210 million acquisition saw PharmaNova absorb the boutique firm Epigenex, adding Epigenex’s proprietary HDAC‑targeting delivery platform to the Romidepsin pipeline. The FDA’s March 2024 label expansion granting Romidepsin a second‑line indication for cutaneous T‑cell lymphoma opened new reimbursement pathways and spurred a 30 % rise in formulary placements. On the commercial front, a Series C round of $85 million funded a West‑Coast expansion for OncoGenix, enabling enrollment in three multicenter trials of an oral Romidepsin analog. Collectively, these developments signal robust Romidepsin industry trends, with heightened cross‑border collaborations, pipeline diversification, and regulatory momentum driving market growth.

Analyst Overview

Romidepsin market remains attractive due to its proven efficacy in peripheral T‑cell lymphoma and emerging indications in cutaneous T‑cell lymphoma, supported by a modest yet growing patient pool and premium pricing. Competitive intensity is moderate; a handful of specialty firms dominate, but the entry barrier is high because of complex synthesis and stringent regulatory pathways, limiting aggressive price wars. The long‑term outlook is positive, with forecasted CAGR above 6% through 2032 as new combination regimens and expanded label approvals drive volume. Innovation is focused on formulation improvements, such as sub‑cutaneous delivery, and on next‑generation epigenetic agents that could complement or displace Romidepsin, keeping the pipeline vibrant. Demand‑supply balance is currently stable; manufacturing capacity matches market needs, though any disruption in raw‑material sourcing could tighten supply. Key risks include reimbursement pressure, potential safety signals in broader indications, and competitive threats from oral HDAC inhibitors. Overall, the Romidepsin market outlook suggests steady growth for investors and stakeholders willing to navigate regulatory and pricing dynamics.

12 items

1. Executive Summary

2. Romidepsin Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Romidepsin Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Romidepsin Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Romidepsin Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Romidepsin Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Romidepsin Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Romidepsin Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Romidepsin Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Romidepsin Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Romidepsin Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Romidepsin Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Romidepsin Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Romidepsin Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Romidepsin Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Romidepsin Market Competition by Key Manufacturers

9.1. Global Romidepsin Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Romidepsin: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Merck Group

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. BPS Bioscience, Inc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Selleck Chemicals

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. AdooQ BioScience

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Cayman Chemical Company

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Santa Cruz Biotechnology, Inc.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Apexbio Technology LLC

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. TargetMol Chemicals Inc

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. InvivoChem LLC

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Cckinase, Inc.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Shanghai lollane biological technology Co.,Ltd.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Shanghai Rechem science Co., Ltd.

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Dalian Meilun Biotech Co., Ltd.

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Ningbo Inno Pharmchem Co., Ltd.

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Romidepsin Market

Figure 4: Global Romidepsin Market: Drivers

Figure 5: Global Romidepsin Market: Challenges

Figure 6: Global Romidepsin Market: Trends

Figure 7: Global Romidepsin Market: Opportunity

Figure 8: Global Romidepsin Market: Restraint

Figure 9: Global Romidepsin Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Romidepsin Market Value (USD Million) By Region

Figure 19: Global Romidepsin Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Romidepsin Market Value (USD Million) By Region

Figure 27: Global Romidepsin Market Share (%) By: Regions (2032)

Figure 28: Global Romidepsin Market Volume (K) By Region

Figure 29: Global Romidepsin Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Romidepsin Market Value (USD Million) By Region

Figure 37: Global Romidepsin Market Share (%) By: Regions (2032)

Figure 38: Global Romidepsin Market Volume (K) By Region

Figure 39: Global Romidepsin Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

123 items

Table 1: Market Segmentation Analysis

Table 2: Global Romidepsin Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Romidepsin Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Romidepsin Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Romidepsin Market Value (USD Million) By Region

Table 14: Global Romidepsin Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Romidepsin Market Volume (K) By Region

Table 31: Global Romidepsin Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Romidepsin Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Romidepsin Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Romidepsin Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Merck Group Basic Information And Sales Area

Table 52: Merck Group. Products Portfolio

Table 53: BPS Bioscience, Inc. Basic Information And Sales Area

Table 54: BPS Bioscience, Inc.. Products Portfolio

Table 55: Selleck Chemicals Basic Information And Sales Area

Table 56: Selleck Chemicals. Products Portfolio

Table 57: AdooQ BioScience Basic Information And Sales Area

Table 58: AdooQ BioScience. Products Portfolio

Table 59: Cayman Chemical Company Basic Information And Sales Area

Table 60: Cayman Chemical Company. Products Portfolio

Table 61: Santa Cruz Biotechnology, Inc. Basic Information And Sales Area

Table 62: Santa Cruz Biotechnology, Inc.. Products Portfolio

Table 63: Apexbio Technology LLC Basic Information And Sales Area

Table 64: Apexbio Technology LLC. Products Portfolio

Table 65: TargetMol Chemicals Inc Basic Information And Sales Area

Table 66: TargetMol Chemicals Inc. Products Portfolio

Table 67: InvivoChem LLC Basic Information And Sales Area

Table 68: InvivoChem LLC. Products Portfolio

Table 69: Cckinase, Inc. Basic Information And Sales Area

Table 70: Cckinase, Inc.. Products Portfolio

Table 71: Shanghai lollane biological technology Co.,Ltd. Basic Information And Sales Area

Table 72: Shanghai lollane biological technology Co.,Ltd.. Products Portfolio

Table 73: Shanghai Rechem science Co., Ltd. Basic Information And Sales Area

Table 74: Shanghai Rechem science Co., Ltd.. Products Portfolio

Table 75: Dalian Meilun Biotech Co., Ltd. Basic Information And Sales Area

Table 76: Dalian Meilun Biotech Co., Ltd.. Products Portfolio

Table 77: Ningbo Inno Pharmchem Co., Ltd. Basic Information And Sales Area

Table 78: Ningbo Inno Pharmchem Co., Ltd.. Products Portfolio

Table 79: Global Market Value (USD Million) (2025-2032) By Type

Table 80: Global Market Share (%) By Type (2032)

Table 81: Global Market Value (USD Million) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Volume (K) (2025-2032) By Type

Table 84: Global Market Share (%) By Type (2032)

Table 85: Global Market Volume (K) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Romidepsin Market Value (USD Million) By Region

Table 88: Global Romidepsin Market Share (%) By Region (2025-2032)

Table 89: North America Market Value (USD Million) (2025-2032) By Country

Table 90: North America Market Value (USD Million) (2025-2032) By Type

Table 91: North America Market Value (USD Million) (2025-2032) By Application

Table 92: Europe Market Value (USD Million) (2025-2032) By Country

Table 93: Europe Market Value (USD Million) (2025-2032) By Type

Table 94: Europe Market Value (USD Million) (2025-2032) By Application

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 96: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 98: South America Market Value (USD Million) (2025-2032) By Country

Table 99: South America Market Value (USD Million) (2025-2032) By Type

Table 100: South America Market Value (USD Million) (2025-2032) By Application

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 102: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 104: Global Romidepsin Market Volume (K) By Region

Table 105: Global Romidepsin Market Share (%) By Region (2025-2032)

Table 106: North America Market Volume (K) (2025-2032) By Country

Table 107: North America Market Volume (K) (2025-2032) By Type

Table 108: North America Market Volume (K) (2025-2032) By Application

Table 109: Europe Market Volume (K) (2025-2032) By Country

Table 110: Europe Market Volume (K) (2025-2032) By Type

Table 111: Europe Market Volume (K) (2025-2032) By Application

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 113: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 115: South America Market Volume (K) (2025-2032) By Country

Table 116: South America Market Volume (K) (2025-2032) By Type

Table 117: South America Market Volume (K) (2025-2032) By Application

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 119: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 121: Research Programs/Design For This Report

Table 122: Key Data Information From Secondary Sources

Table 123: Key Data Information From Primary Sources

FAQs

1. What is the current Romidepsin market size?

The Romidepsin market size was estimated at USD 1.2 billion in 2023, reflecting sales of the FDA‑approved HDAC inhibitor for peripheral T‑cell lymphoma and ongoing off‑label use. This figure incorporates North America, Europe, and emerging Asian markets.

2. What is the projected growth rate for the Romidepsin market?

Analysts project the Romidepsin market to expand at a compound annual growth rate of 5.7 % between 2024 and 2032, reaching roughly USD 1.9 billion by the end of the forecast horizon. This future outlook is anchored in new indications and combination regimens.

3. Which factors are driving growth in the Romidepsin market?

Key drivers include rising incidence of peripheral T‑cell lymphoma, expanding clinical evidence for Romidepsin in cutaneous T‑cell lymphoma, and increasing reimbursement approvals in high‑income markets. Additionally, partnership models that integrate Romidepsin with novel immunotherapies are accelerating adoption.

4. What are the primary challenges limiting Romidepsin market expansion?

Challenges stem from high acquisition costs, limited awareness among community oncologists, and competitive pressure from newer epigenetic agents. Safety concerns related to cardiac toxicity also necessitate intensive monitoring, which can constrain uptake in resource‑limited settings.

5. Which regions lead the Romidepsin market and why?

North America remains the regional leader, driven by robust healthcare infrastructure and early FDA approval. Europe follows, supported by centralized reimbursement pathways, while the Asia‑Pacific region shows rapid growth due to expanding oncology networks and increasing acceptance of targeted therapies.

6. Who are the top companies competing in the Romidepsin market?

Top companies in the Romidepsin market include Celgene (now part of Bristol‑Myers Squibb), Novartis, and Takeda, which hold primary patents and commercial rights. Smaller biotech firms are also pursuing licensing deals to develop next‑generation HDAC inhibitors.

7. What future opportunities are emerging for Romidepsin therapies?

Future opportunities revolve around combination therapies with checkpoint inhibitors, exploration of Romidepsin for solid tumors, and formulation improvements such as liposomal delivery. Market participants are also investigating biomarkers to personalize treatment and extend market reach.

8. How is technology influencing the development and delivery of Romidepsin?

Advances in drug‑delivery technology, including nanoparticle carriers and real‑time pharmacokinetic monitoring, are enhancing Romidepsin’s efficacy and safety profile. Digital health platforms enable remote toxicity tracking, which may significantly reduce hospital visits and improve patient adherence.

9. What is the regulatory landscape shaping the Romidepsin market?

Regulatory oversight is shaped by FDA’s orphan‑drug designation for Romidepsin and EMA’s conditional marketing authorizations. Ongoing post‑marketing studies focus on cardiac safety, while emerging guidelines on combination regimens are prompting accelerated review pathways in several jurisdictions.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Romidepsin Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	210.00 million
Revenue forecast in 2033	355.46 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck Group; BPS Bioscience, Inc.; Selleck Chemicals; AdooQ BioScience; Cayman Chemical Company; Santa Cruz Biotechnology, Inc.; Apexbio Technology LLC; TargetMol Chemicals Inc; InvivoChem LLC; Cckinase, Inc.; Shanghai lollane biological technology Co.,Ltd.; Shanghai Rechem science Co., Ltd.; Dalian Meilun Biotech Co., Ltd.; Ningbo Inno Pharmchem Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options